|Bid||138.70 x 900|
|Ask||139.30 x 800|
|Day's Range||137.91 - 140.00|
|52 Week Range||118.62 - 148.32|
|Beta (3Y Monthly)||0.53|
|PE Ratio (TTM)||276.44|
|Earnings Date||Jan 21, 2019 - Jan 25, 2019|
|Forward Dividend & Yield||3.60 (2.58%)|
|1y Target Est||145.63|
Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest market moves.
Johnson & Johnson’s (JNJ) women’s health business generated revenue of $269.0 million in the third quarter compared to $270.0 million in the third quarter of 2017. In the US and international markets in the quarter, the business generated revenues of $3.0 million and $266.0 million, respectively.
Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.
In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).
In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.
The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren't sure what the foreseeable future holds. In simplest terms, it's just plain stressful. It's times like these when the "old school" approach of buy and hold -- meaning buy it and forget about it -- starts to sound compelling again. In other words, forget the day-to-day battles. Sit back and trust that time will do the heavy lifting for you. To that end, here's a rundown of 10 large-cap names that are well-suited for that precise approach. They're all S&P 500 stocks, and more than that, they're all names that don't require constant babysitting. You can count on them more or less being the same company a year from now, and even five years from now. In no particular order... SEE ALSO FROM KIPLINGER: 10 S&P 500 Stocks to Buy for Long-Term Outperformance
Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.
How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.
Investing.com - Intuitive Surgical (NASDAQ:ISRG) reported third quarter earnings that missed analyst's expectations on Thursday and revenue that topped forecasts.
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.
Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.
As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.
NEW BRUNSWICK, N.J., Oct. 18, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2018 of $0.90 per share on the company's common stock. The dividend is payable on December 11, 2018 to shareholders of record at the close of business on November 27, 2018. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
After taking a Peninsula startup through a billion-dollar acquisition, Kathy Glaub and Anthony Ford are at it again. The duo are leading CuraSen Theraepeutics Inc., which said Wednesday that it had raised $54.5 million to target Alzheimer's disease, Parkinson's disease and other, less-common neurodegenerative diseases. The Series A round was led by New Leaf Venture Partners and included Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Pappas Capital and Johnson & Johnson's corporate venture arm.
Investing.com - Abbott Labs (NYSE:ABT) reported third quarter earnings that beat analyst's expectations on Wednesday and revenue that topped forecasts.
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / U.S. equities closed higher on Tuesday, driven by upbeat corporate earnings and strong economic data. According to the Federal Reserve, U.S. industrial production ...
SINGAPORE (AP) — Asian markets rose on Wednesday as robust U.S. corporate earnings and encouraging data assuaged worries about softening global growth.
"When the Fed bears are away, the stock bulls will play," Jim Cramer told his Mad Money viewers Tuesday, after the markets mounted an impressive relief rally. Cramer reminded viewers that a panic is a terrible thing to waste, which is why the smart money was buying into the recent declines and not selling out of fear.
Johnson & Johnson reported higher revenue and profit for the third quarter, as improved pharmaceutical sales helped offset weakness in its medical-device business. Global sales of J&J’s cancer drugs, which include Zytiga for prostate cancer and blood-cancer treatments Darzalex and Imbruvica, jumped 36% for the quarter. “Our positive view on pharma is offset by ongoing challenges to the company’s medical device and consumer franchises,” JPMorgan analyst Chris Schott wrote in a research note.